AIM ImmunoTech Releases Virtual Investor “What This Means Segment”
AIM ImmunoTech (NYSE American: AIM) has released a Virtual Investor segment featuring CEO Thomas K. Equels and Professor Casper H.J. van Eijck from Erasmus Medical Center discussing their Phase 1b/2 clinical trial DURIPANC. The trial investigates the combination of AIM's Ampligen® and AstraZeneca's Imfinzi® for treating late-stage pancreatic cancer.
The Erasmus MC Safety Committee has approved advancing to Phase 2 after reviewing Phase 1 safety data, which showed the combination treatment was generally well-tolerated with no treatment-related severe adverse events or dose-limiting toxicities. The study is being conducted as an investigator-initiated, exploratory, open-label, single-center trial in the Netherlands at Erasmus MC.
AIM ImmunoTech (NYSE American: AIM) ha rilasciato un segmento di Investor Virtual che presenta il CEO Thomas K. Equels e il Professor Casper H.J. van Eijck dell'Erasmus Medical Center, i quali discutono del loro trial clinico di Fase 1b/2 DURIPANC. Questo trial esamina la combinazione di Ampligen® di AIM e Imfinzi® di AstraZeneca per il trattamento del cancro pancreatico avanzato.
Il Comitato di Sicurezza dell'Erasmus MC ha approvato l'avanzamento alla Fase 2 dopo aver esaminato i dati di sicurezza della Fase 1, che hanno mostrato che il trattamento combinato è stato generalmente ben tollerato, senza eventi avversi gravi correlati al trattamento o tossicità limitanti della dose. Lo studio è condotto come uno studio esplorativo, aperto, monoinstituzionale e iniziato da un investigatore nei Paesi Bassi presso Erasmus MC.
AIM ImmunoTech (NYSE American: AIM) ha lanzado un segmento de Inversor Virtual que presenta al CEO Thomas K. Equels y al Profesor Casper H.J. van Eijck del Erasmus Medical Center, quienes discuten su ensayo clínico de Fase 1b/2 DURIPANC. El ensayo investiga la combinación del Ampligen® de AIM y el Imfinzi® de AstraZeneca para el tratamiento del cáncer pancreático en etapa avanzada.
El Comité de Seguridad del Erasmus MC ha aprobado pasar a la Fase 2 después de revisar los datos de seguridad de la Fase 1, los cuales indicaron que el tratamiento combinado fue generalmente bien tolerado, sin eventos adversos graves relacionados con el tratamiento o toxicidades limitantes de dosis. El estudio se lleva a cabo como un ensayo exploratorio, abierto y monoinstitucional iniciado por un investigador en los Países Bajos en Erasmus MC.
AIM ImmunoTech (뉴욕증권거래소: AIM)이 Phase 1b/2 임상시험 DURIPANC에 대해 CEO Thomas K. Equels와 에라스무스 의과대학의 Casper H.J. van Eijck 교수와 함께 토론하는 가상 투자자 세그먼트를 발표했습니다. 이 임상시험에서는 AIM의 Ampligen®과 AstraZeneca의 Imfinzi®의 조합이 말기 췌장암 치료에 대한 효과를 조사하고 있습니다.
에라스무스 MC 안전위원회는 1단계 안전성 데이터를 검토한 후 2단계로의 진행을 승인했습니다. 이 데이터는 조합 치료가 일반적으로 잘 견디며, 치료와 관련된 심각한 부작용이나 용량 제한 독성이 없음을 보여주었습니다. 이 연구는 네덜란드 에라스무스 MC에서 연구자가 주도하여 시작된 탐색적이고, 열린 라벨의 단일 센터 시험으로 진행되고 있습니다.
AIM ImmunoTech (NYSE American: AIM) a lancé un segment d'Investisseur Virtuel mettant en vedette le PDG Thomas K. Equels et le Professeur Casper H.J. van Eijck du Centre Médical Erasmus discutant de leur essai clinique de Phase 1b/2 DURIPANC. L'essai étudie la combinaison de l'Ampligen® d'AIM et de l'Imfinzi® d'AstraZeneca pour traiter le cancer du pancréas à un stade avancé.
Le Comité de Sécurité de l'Erasmus MC a approuvé le passage à la Phase 2 après avoir examiné les données de sécurité de la Phase 1, qui ont montré que le traitement combiné était généralement bien toléré, sans événements indésirables graves liés au traitement ni toxicités limitantes de dose. L'étude est menée comme une étude exploratoire, ouverte et à centre unique, initiée par un investigateur aux Pays-Bas au Erasmus MC.
AIM ImmunoTech (NYSE American: AIM) hat einen virtuellen Investorensegment veröffentlicht, in dem CEO Thomas K. Equels und Professor Casper H.J. van Eijck vom Erasmus Medical Center über ihre Phase 1b/2-klinische Studie DURIPANC sprechen. Die Studie untersucht die Kombination von AIMs Ampligen® und AstraZenecas Imfinzi® zur Behandlung von fortgeschrittenem Pankreaskarzinom.
Das Sicherheitsteam des Erasmus MC hat der Fortführung zur Phase 2 zugestimmt, nachdem die Sicherheitsdaten der Phase 1 überprüft wurden, die zeigten, dass die Kombinationstherapie im Allgemeinen gut verträglich war und keine behandlungsbedingten schweren Nebenwirkungen oder dosislimitierten Toxizitäten auftraten. Die Studie wird als untersucherinitiierte, explorative, offene Einrichtungsstudie in den Niederlanden am Erasmus MC durchgeführt.
- Phase 1 trial demonstrated favorable safety profile with no severe adverse events
- Received approval to advance to Phase 2 of the DURIPANC study
- Strategic collaboration with major pharmaceutical company AstraZeneca
- None.
Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM’s Ampligen® (rintatolimod) and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of late-stage pancreatic cancer (“DURIPANC”)
Watch the “What This Means” segment here
OCALA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that AIM CEO Thomas K. Equels and Prof. Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at the Erasmus Medical Center (“Erasmus MC”) and Coordinating Investigator for the DURIPANC study in late-stage pancreatic cancer, participated in a Virtual Investor “What This Means” segment. Access the segment here.
As part of the segment, Mr. Equels and Professor van Eijck discuss the recent approval from the Erasmus MC Safety Committee to proceed with the Phase 2 Study of Ampligen® and AstraZeneca’s Imfinzi as a potential combination treatment for late-stage pancreatic cancer. DURIPANC is an investigator-initiated, exploratory, open-label, single-center study in the Netherlands at Erasmus MC. The approval to proceed to Phase 2 was granted following the Safety Committee’s review of the complete Phase 1 safety data, which found the combination treatment to be generally well-tolerated with no treatment-related severe adverse events or dose-limiting toxicities.
The Virtual Investor “What this Means” segment featuring AIM ImmunoTech is now available here.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy for pancreatic cancer. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Investor Contact:
JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com
FAQ
What were the Phase 1 safety results for AIM's DURIPANC pancreatic cancer trial?
When did AIM ImmunoTech receive approval to proceed to Phase 2 of the DURIPANC trial?
Where is AIM ImmunoTech's DURIPANC clinical trial being conducted?
What is the purpose of AIM's DURIPANC clinical trial?
